The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of VR-EPOCH for the management of Richter’s syndrome
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the use of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for the management of Richter’s syndrome, highlighting the rates of progression-free survival (PFS) and overall survival (OS) observed in patients treated with this regimen, and ongoing trials in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
